This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. Drugmaker Biogen has until 2030 to complete a study confirming whether the new drug truly slows the brain-destroying disease. That’s under the terms of the Food and Drug Administration’s conditional approval of the drug, a decision that has been praised by patients as overdue and condemned by the agency’s own outside experts. Credit: Biogen via AP, File
When a controversial Alzheimer’s drug won U.S. approval, surprise over the decision quickly turned to shock at how long it might take to find out if it really works—nine years.
В казино можно найти не только автоматы. На основных сайтах предусмотрен раздел «Лайв». Там пользователи найдут игры с картами, настольные игры, игра с дилером...
